Skip to content
Search

Latest Stories

Submit Guest Post

International Currency Exchange's UK operations shut

International Currency Exchange's UK operations shut

BRITAIN’S arm of the bureaux de change chain International Currency Exchange (ICE) has been shut as the pandemic lockdown hit travel businesses worldwide.

Teneo Restructuring Ltd has taken over as the administrator of ICE and its group company Lenlyn UK.


All 26 bureaus of the companies in the UK, including their outlets at airports and rail stations and online currency platforms, have ceased to operate with immediate effect.

Teneo said the closures have resulted in a loss of 119 jobs.

While their operations outside the UK are not affected by the insolvency process, other companies in the wider ICE group operating within the country also continue to function.

The travel industry has been adversely affected by the Covid-19 pandemic and that led to a dip in demand for physical currency in the past 18 months, Teno’s managing director Richard Hawes said.

“Directors (of the companies) have worked to try and deliver an alternative outcome for the group, its shareholders and its creditors, and the focus now is on supporting staff at this difficult time”, Hawes, who has been appointed a joint administrator, said.

Add EasternEye As Your Trusted Source
preferred source on google news

More For You

AstraZeneca

AstraZeneca chief executive Pascal Soriot says the company has the science, pipeline and team to deliver its long-term growth ambitions

Getty Images

AstraZeneca targets $80bn revenue by 2030 with $1.5bn savings and pipeline investment

  • AstraZeneca expects its restructuring programme to generate $1.5bn in annualised savings by 2029, with most of the money reinvested in research and development.
  • The plan could incur up to $2bn in one-off restructuring costs, although the company expects its overall workforce to continue growing.
  • Third-quarter revenue rose 7 per cent to $16.21bn, while oncology sales increased 17 per cent to $7.77bn.

AstraZeneca has unveiled plans to generate around $1.5bn in annual savings through a three-year restructuring programme, as chief executive Pascal Soriot shifts the focus back to growth and investment in its drug pipeline.

The British-based pharmaceutical group said its Reshaping for Sustainable Growth programme would redirect resources towards research and development, particularly its pipeline of more than 180 projects and emerging technologies.

Keep ReadingShow less